Teva launches generic Adenoscan in U.S.

Teva (TEVA) announces the U.S. launch of generic Adenoscan, the arrhythmias treatment marketed by Astellas Pharma (ALPMF.PK, ALPMY.PK).

TEVA enjoys 180 days of market exclusivity by virtue of being first to file.

Adenoscan has annual U.S. sales of around $65M. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs